The capacity of iPSCs to capture CML genetic aberrations, self-renew indefinitely and differentiate into blood cells allows for the production of pure populations of patient-specific BCR-ABL+ LSC-like cells in unlimited numbers for functional studies and drug screening. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.